Table of Content

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED FOR THE STUDY 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 RESEARCH DATA 17
2.2 SECONDARY DATA 17
2.2.1 KEY DATA FROM SECONDARY SOURCES 18
2.3 PRIMARY DATA 18
2.3.1 KEY DATA FROM PRIMARY SOURCES 20
2.4 MARKET SIZE ESTIMATION 21
2.4.1 BOTTOM-UP APPROACH 21
2.4.2 TOP-DOWN APPROACH 22
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.6 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

4 PREMIUM INSIGHTS 29
4.1 LEUKEMIA THERAPEUTICS: MARKET OVERVIEW 29
4.2 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE & MODE OF
ADMINISTRATION (2019) 30
4.3 GEOGRAPHICAL SNAPSHOT OF THE LEUKEMIA THERAPEUTICS MARKET 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 DRIVERS 33
5.2.1.1 Rising prevalence of leukemia 33
5.2.1.1.1 Growth in geriatric population 33
5.2.1.1.2 Rising cancer occurrence among children 33
5.2.1.2 Introduction of innovative therapies 34
5.2.2 RESTRAINTS 34
5.2.2.1 Complexities in manufacturing 34
5.2.3 OPPORTUNITIES 35
5.2.3.1 Growth opportunities in emerging economies 35

6 LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA 36
6.1 INTRODUCTION 37
6.2 CHRONIC MYELOID LEUKEMIA 37
6.2.1 CHRONIC MYELOID LEUKEMIA ACCOUNTS FOR THE LARGEST SHARE OF
THE LEUKEMIA THERAPEUTICS MARKET PRIMARILY DUE TO THE HIGH INCIDENCE OF THIS DISEASE WORLDWIDE 37
6.3 CHRONIC LYMPHOCYTIC LEUKEMIA 38
6.3.1 THE INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA INCREASES WITH
AGE AND IS MORE COMMON IN MEN THAN WOMEN 38
6.4 ACUTE LYMPHOCYTIC LEUKEMIA 39
6.4.1 ACUTE LYMPHOCYTIC LEUKEMIA MOSTLY AFFECTS CHILDREN BETWEEN

3 AND 7 YEARS OF AGE 39
6.5 ACUTE MYELOID LEUKEMIA 40
6.5.1 ACUTE MYELOID LEUKEMIA IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS 40

7 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 41
7.1 INTRODUCTION 42
7.2 TARGETED DRUGS & IMMUNOTHERAPY 42
7.2.1 TARGETED DRUGS & IMMUNOTHERAPY SEGMENT ACCOUNTS FOR THE LARGER MARKET SHARE DUE TO THE HIGHER EFFICACY & SUCCESS RATE ASSOCIATED WITH THEM AS COMPARED TO CHEMOTHERAPY 42
7.3 CHEMOTHERAPY 46
7.3.1 CHEMOTHERAPY IS EFFECTIVE AND ESSENTIAL FOR CANCERS SUCH AS LEUKEMIA THAT HAVE SPREAD THROUGHOUT THE BODY 46

8 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE 50
8.1 INTRODUCTION 51
8.2 SMALL MOLECULES 51
8.2.1 THE SMALL STRUCTURE AND CHEMICAL COMPOSITION OF SMALL MOLECULES HELP THEM TO EASILY PENETRATE CELL MEMBRANES 51
8.3 BIOLOGICS 53
8.3.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 53

9 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION 54
9.1 INTRODUCTION 55
9.2 ORAL MODE 55
9.2.1 DRUGS ADMINISTERED ORALLY HAVE LESSER COMPLICATIONS 55
9.3 INJECTABLE MODE 56
9.3.1 INJECTABLE MODE OF ADMINISTRATION IS LESS PREFERRED THAN
THE ORAL MODE OF ADMINISTRATION 56

10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER 58
10.1 INTRODUCTION 59
10.2 MALES 60
10.2.1 MEN ARE AT HIGHER RISK OF DEVELOPING LEUKEMIA THAN WOMEN 60
10.3 FEMALES 61
10.3.1 ACUTE LYMPHOCYTIC LEUKEMIA REMAINS COMMON AMONG WOMEN 61

11 LEUKEMIA THERAPEUTICS MARKET, BY REGION 62
11.1 INTRODUCTION 63
11.2 NORTH AMERICA 64
11.2.1 US 66
11.2.1.1 US accounted for the largest share of the North American market due to the high prevalence of leukemia in the country 66
11.2.2 CANADA 70
11.2.2.1 Government initiatives to support leukemia research and develop novel immunotherapies is expected to support the growth of the Canadian leukemia therapeutics market 70
11.3 EUROPE 71
11.3.1 GERMANY 73
11.3.1.1 Germany has a strong foundation for R&D, including over 1,000 public and private institutions 73
11.3.2 UK 74
11.3.2.1 Rising geriatric population in the country to drive market growth as the incidence of cancer is higher in the geriatric population 74
11.3.3 FRANCE 79
11.3.3.1 Rising R&D expenditure is a major growth driver in France 79
11.3.4 REST OF EUROPE 80
11.4 ASIA PACIFIC 82
11.4.1 JAPAN 83
11.4.1.1 Comparatively lenient regulations and rising geriatric population will drive market growth 83
11.4.2 CHINA 85
11.4.2.1 Favorable investments and government support will contribute to
the growth of the Chinese market 85
11.4.3 INDIA 86
11.4.3.1 Shortage of skilled professionals may restrain the growth of
the Indian market 86
11.4.4 ROAPAC 88
11.5 REST OF THE WORLD 90
?

12 COMPETITIVE LANDSCAPE 92
12.1 OVERVIEW 92
12.2 MARKET RANKING ANALYSIS, 2018 92
12.3 KEY STRATEGIES 93
12.3.1 REGULATORY APPROVALS/LAUNCHES 93
12.3.2 ACQUISITIONS 94
12.3.3 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 95
12.4 COMPETITIVE LEADERSHIP MAPPING (2018) 96
12.4.1 VENDOR INCLUSION CRITERIA 96
12.4.2 VISIONARY LEADERS 96
12.4.3 INNOVATORS 96
12.4.4 DYNAMIC DIFFERENTIATORS 96
12.4.5 EMERGING COMPANIES 96
12.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018) 98
12.5.1 PROGRESSIVE COMPANIES 98
12.5.2 STARTING BLOCKS 98
12.5.3 RESPONSIVE COMPANIES 98
12.5.4 DYNAMIC COMPANIES 98

13 COMPANY PROFILES 100
(Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View)*
13.1 NOVARTIS AG 100
13.2 ABBVIE 102
13.3 BRISTOL-MYERS SQUIBB 105
13.4 F. HOFFMANN-LA ROCHE 107
13.5 SANOFI 109
13.6 PFIZER 110
13.7 AMGEN 112
13.8 GILEAD SCIENCES 114
13.9 TAKEDA 116
13.10 CELGENE 118
* Business Overview, Products Offered, Recent Developments, Regulatory Approvals, and MnM View might not be captured in case of unlisted companies.

14 APPENDIX 120
14.1 INSIGHTS FROM INDUSTRY EXPERTS 120
14.2 DISCUSSION GUIDE 121
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 124
14.4 AVAILABLE CUSTOMIZATIONS 126
14.5 RELATED REPORTS 126
14.6 AUTHOR DETAILS 127



List of Figures



FIGURE 1 RESEARCH DESIGN 17
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 19
FIGURE 3 LEUKEMIA THERAPEUTICS MARKET: BOTTOM-UP APPROACH 21
FIGURE 4 LEUKEMIA THERAPEUTICS MARKET: TOP-DOWN APPROACH 22
FIGURE 5 DATA TRIANGULATION METHODOLOGY 23
FIGURE 6 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2019 VS. 2024 (USD MILLION) 25
FIGURE 7 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2019 VS. 2024 (USD MILLION) 26
FIGURE 8 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION 2019 VS. 2024 (USD MILLION) 26
FIGURE 9 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE 2019 VS. 2024 (USD MILLION) 27
FIGURE 10 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2019 VS. 2024 (USD MILLION) 27
FIGURE 11 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2019 VS. 2024 (USD MILLION) 28
FIGURE 12 RISING INCIDENCE RATE OF LEUKEMIA TO DRIVE MARKET GROWTH 29
FIGURE 13 ORAL AND TARGETED DRUGS & IMMUNOTHERAPY SEGMENTS TO DOMINATE
THE MARKET IN 2019 30
FIGURE 14 US TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 31
FIGURE 15 LEUKEMIA THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 32
FIGURE 16 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET SNAPSHOT 64
FIGURE 17 KEY DEVELOPMENTS IN THE LEUKEMIA THERAPEUTICS MARKET (2016-2018) 92
FIGURE 18 MNM DIVE-VENDOR COMPARISON MATRIX: LEUKEMIA THERAPEUTICS MARKET 97
FIGURE 19 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS:
LEUKEMIA THERAPEUTICS MARKET 99
FIGURE 20 NOVARTIS: COMPANY SNAPSHOT (2018) 100
FIGURE 21 ABBVIE INC.: COMPANY SNAPSHOT (2018) 102
FIGURE 22 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2018) 105
FIGURE 23 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2018) 107
FIGURE 24 SANOFI: COMPANY SNAPSHOT (2018) 109
FIGURE 25 PFIZER: COMPANY SNAPSHOT (2018) 110
FIGURE 26 AMGEN: COMPANY SNAPSHOT (2018) 112
FIGURE 27 GILEAD SCIENCES: COMPANY SNAPSHOT (2018) 114
FIGURE 28 TAKEDA: COMPANY SNAPSHOT (2018) 116
FIGURE 29 CELGENE: COMPANY SNAPSHOT (2018) 118

 

List of Tables



TABLE 1 LEUKEMIA PATIENTS, BY REGION 33
TABLE 2 ACUTE LYMPHOCYTIC LEUKEMIA PATIENTS IN US 34
TABLE 3 LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 37
TABLE 4 CHRONIC MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION) 38
TABLE 5 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET, BY REGION 2017–2024 (USD MILLION) 39
TABLE 6 ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY REGION 2017–2024 (USD MILLION ) 39
TABLE 7 ACUTE MYELOID LEUKEMIA MARKET, BY REGION, 2017–2024 (USD MILLION) 40
TABLE 8 LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 42
TABLE 9 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 43
TABLE 10 TARGETED DRUGS AND IMMUNOTHERAPY MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 43
TABLE 11 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 44
TABLE 12 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 44
TABLE 13 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 45
TABLE 14 TARGETED DRUGS AND IMMUNOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 45
TABLE 15 FEW EXAMPLES OF CHEMOTHERAPY DRUGS 46
TABLE 16 CHEMOTHERAPY MARKET FOR LEUKEMIA, BY REGION 2017–2024 (USD MILLION) 46
TABLE 17 CHEMOTHERAPY MARKET, BY LEUKEMIA TYPE, 2017–2024 (USD MILLION) 47
TABLE 18 CHEMOTHERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 47
TABLE 19 CHEMOTHERAPY MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2017–2024 (USD MILLION) 48
TABLE 20 CHEMOTHERAPY MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION 2017–2024 (USD MILLION) 48
TABLE 21 CHEMOTHERAPY MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION 2017–2024 (USD MILLION) 49
TABLE 22 LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE 2017–2024 (USD MILLION) 51
TABLE 23 FEW IMPORTANT SMALL MOLECULES USED TO TREAT DIFFERENT LEUKEMIA TYPE 52
TABLE 24 LEUKEMIA THERAPEUTICS MARKET FOR SMALL MOLECULES, BY REGION 2017–2024 (USD MILLION) 52
TABLE 25 FEW IMPORTANT BIOLOGICS FOR THE TREATMENT OF DIFFERENT LEUKEMIA TYPE 53
TABLE 26 LEUKEMIA THERAPEUTICS MARKET FOR BIOLOGICS, BY REGION 2017–2024 (USD MILLION) 53
TABLE 27 LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION 2017–2024 (USD MILLION) 55
TABLE 28 LEUKEMIA THERAPEUTICS MARKET FOR ORAL MODE OF ADMINISTRATION BY REGION, 2017–2024 (USD MILLION) 56
TABLE 29 LEUKEMIA THERAPEUTICS MARKET FOR INJECTABLE MODE OF ADMINISTRATION, BY REGION, 2017–2024 (USD MILLION) 57
TABLE 30 LEUKEMIA AT A GLANCE (US) 59
TABLE 31 GLOBAL LEUKEMIA CASES (2018), BY COUNTRY AND GENDER &
FORECAST (2020) 59
TABLE 32 LEUKEMIA INCIDENCE AND DEATHS, BY GENDER (2018) 60
TABLE 33 LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 60
TABLE 34 LEUKEMIA THERAPEUTICS MARKET FOR MALES, BY REGION 2017–2024 (USD MILLION) 61
TABLE 35 LEUKEMIA THERAPEUTICS MARKET FOR FEMALES, BY REGION 2017–2024 (USD MILLION) 61
TABLE 36 LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 37 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 65
TABLE 38 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 65
TABLE 39 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017–2024 (USD MILLION) 65
TABLE 40 NORTH AMERICA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 66
TABLE 41 US: LEUKEMIA AT A GLANCE 66
TABLE 42 US: LEUKEMIA, BY TYPE (2017 VS. 2018) 67
TABLE 43 US: LEUKEMIA NEW CASES & DEATHS, BY STATE (2019) 67
TABLE 44 US: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 69
TABLE 45 US: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 69
TABLE 46 US: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 70
TABLE 47 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 70
TABLE 48 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 71
TABLE 49 CANADA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 71
TABLE 50 RESEARCH FUNDING: EUROPEAN OVERVIEW 71
TABLE 51 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 72
TABLE 52 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 72
TABLE 53 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 72
TABLE 54 EUROPE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 73
TABLE 55 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 73
TABLE 56 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 74
TABLE 57 GERMANY: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 74
TABLE 58 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATE PER 100,000 POPULATION (ACUTE LYMPHOCYTIC LEUKEMIA) 75
TABLE 59 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC LYMPHOCYTIC LEUKEMIA) 76
TABLE 60 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (ACUTE MYELOID LEUKEMIA) 76
TABLE 61 UK: NUMBER OF NEW CASES, CRUDE, AND AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION (CHRONIC MYELOID LEUKEMIA) 77
TABLE 62 UK: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 78
TABLE 63 UK: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 78
TABLE 64 UK: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 78
TABLE 65 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 79
TABLE 66 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 79
TABLE 67 FRANCE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 80
TABLE 68 ROE: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 81
TABLE 69 ROE: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 81
TABLE 70 ROE: LEUKEMIA THERAPEUTICS MARKET, BY GENDER, 2017–2024 (USD MILLION) 81
TABLE 71 APAC: LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 82
TABLE 72 APAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 82
TABLE 73 APAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 83
TABLE 74 APAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 83
TABLE 75 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 84
TABLE 76 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 84
TABLE 77 JAPAN: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 85
TABLE 78 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 85
TABLE 79 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 86
TABLE 80 CHINA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 86
TABLE 81 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 87
TABLE 82 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 87
TABLE 83 INDIA: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 87
TABLE 84 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 88
TABLE 85 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 88
TABLE 86 ROAPAC: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 89
TABLE 87 ROW: LEUKEMIA THERAPEUTICS MARKET, BY LEUKEMIA TYPE 2017–2024 (USD MILLION) 90
TABLE 88 ROW: LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE 2017–2024 (USD MILLION) 90
TABLE 89 ROW: LEUKEMIA THERAPEUTICS MARKET, BY GENDER 2017–2024 (USD MILLION) 91
TABLE 90 LEUKEMIA THERAPEUTICS MARKET RANKING BY KEY PLAYER, 2018 92